The global challenge of new classes of antibacterial agents: an industry perspective
- 1 October 2015
- journal article
- review article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 24, 7-11
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Antibiotic Resistance — Problems, Progress, and ProspectsNew England Journal of Medicine, 2014
- A three-step plan for antibioticsNature, 2014
- Policy: An intergovernmental panel on antimicrobial resistanceNature, 2014
- The FDA Reboot of Antibiotic DevelopmentAntimicrobial Agents and Chemotherapy, 2013
- The Scourge of Antibiotic Resistance: The Important Role of the EnvironmentClinical Infectious Diseases, 2013
- Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agentsBioorganic & Medicinal Chemistry Letters, 2012
- Antibiotics in development targeting protein synthesisAnnals of the New York Academy of Sciences, 2011
- Control of Lipopolysaccharide Biosynthesis by FtsH-Mediated Proteolysis of LpxC Is Conserved in Enterobacteria but Not in All Gram-Negative BacteriaJournal of Bacteriology, 2011
- Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative BacilliAntimicrobial Agents and Chemotherapy, 2008
- Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic propertiesProceedings of the National Academy of Sciences, 2007